Opendata, web and dolomites

STRICT SIGNED

SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRICT project word cloud

Explore the words cloud of the STRICT project. It provides you a very rough idea of what is the project "STRICT" about.

associate    recruit    cardinor    boost    quality    house    device    levels    saving    blood    health    global    normal    alone    cardiac    market    company    biomarkers    patients    defibrillator    worldwide    coming    20k    least    sn    accurate    acquiring    shown    survival    diagnostic    35    killer    arrhythmias    positioning    death    globally    ecg    data    lives    exams    arrythmia    linked    sudden    victims    detect    innovation    physical    diagnosis    decision    trl8    cardiologists    maturation    pinpoint    patient    patented    competitive    caused    regime    eligible    ventricular    cvd    skills    reducing    icd    echocardiogram    burden    assurance    implantable    ivd    ventricle    biomarker    icds    correlation    surgery    ejection    status    biomedical    difficult    never    25    lt    advantage    67    sme    overtreatment    3b    scd    cardioverter    secretoneurin    disease    unknowingly    ask    stratify    lvef    risk    expertise    cardiovascular    mortality    left    vitro    activated    51   

Project "STRICT" data sheet

The following table provides information about the project.

Coordinator
CARDINOR AS 

Organization address
address: GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 119˙805 €
 EC max contribution 119˙805 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-2019-02
 Funding Scheme CSA
 Starting year 2019
 Duration (year-month-day) from 2019-12-15   to  2020-12-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDINOR AS NO (OSLO) coordinator 119˙805.00

Map

 Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

bsnEA (2020)

Business Support Network – East Anatolia

Read More  

PROBIM (2020)

PRO Business Innovation Moldova

Read More  

H2020 SGA4 (2020)

EEN Northern Netherlands - H2020 SGA4 - Period 2020/21

Read More